Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study

Area of Science:

• Psychiatry
• Clinical Pharmacology
• Neuroscience

Background:

• Schizophrenia treatment often involves finding an optimal antipsychotic dose.
• Extrapyramidal side effects are a common concern with antipsychotic medications like haloperidol.

Purpose of the Study:

• To identify a clinical marker for optimal haloperidol dosing in acute schizophrenia.
• To correlate plasma haloperidol levels with the neuroleptic threshold and therapeutic efficacy.

Main Methods:

• Rapidly adjusted daily haloperidol doses in 33 acutely psychotic schizophrenic patients.
• Identified the neuroleptic threshold by the appearance of slight hypokinesia-rigidity.
• Measured plasma haloperidol levels at the neuroleptic threshold.

Main Results:

• The mean haloperidol dose at the neuroleptic threshold was 4.2 +/- 2.4 mg/day.
• Plasma haloperidol levels at this threshold averaged 4.9 +/- 2.9 ng/ml.
• Sixty-seven percent of patients showed significant improvement within 3 weeks at these doses, with minimal coarse extrapyramidal side effects.

Conclusions:

• The neuroleptic threshold is a practical clinical indicator for haloperidol dosing.
• This threshold identifies plasma haloperidol levels associated with therapeutic benefits and reduced side effects.
• Optimizing haloperidol dosage via the neuroleptic threshold may improve schizophrenia treatment outcomes.